Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
Virtual event on Thursday, February 15, 2024 at 12:00 PM ET will feature KOLs Larry Ereshefsky, PharmD, BCPP, FCCP, of Follow the Molecule and Mark Opler, PhD, MPH of WCG
CUPERTINO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that
seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it will host a key opinion leader (KOL) event on
Thursday, February 15, 2024 at 12:00 PM ET, featuring Larry Ereshefsky, PharmD, BCPP (Retired professor of Psychiatry, Pharmacology and Psychiatry, The University of Texas; Chief Scientific
Officer, Owner, Follow the Molecule LLC) and Mark Opler, PhD, MPH (Chief Research Officer at WCG Inc., Executive Director of the PANSS Institute), who will discuss the unmet medical need and
current treatment landscape for patients suffering from acute to chronic symptoms of schizophrenia, and brilaroxazine (RP5063), a next-generation serotonin/dopamine modulator, as a potential
treatment. To register, click
here.
The event will focus on reviewing Reviva's positive topline results and successful completion of pivotal Phase 3 RECOVER trial evaluating the efficacy, safety, and tolerability of once-daily brilaroxazine in adults with acute schizophrenia, as well as the Company's ongoing enrollment in the one-year open label extension (OLE) trial and the initiation of registrational Phase 3 RECOVER-2 trial.
A live question and answer session will follow the formal presentations.
Lesen Sie auch
About Larry Ereshefsky, PharmD, BCPP, FCCP
Larry Ereshefsky, PharmD, BCPP, FCCP, over his 45 years’ career, applies his experience as a clinician, scientist, and investigator, to develop treatments and innovate clinical methodologies to
make a difference in the lives of patients with Neurodegenerative and Psychiatric Disorders. He has contributed significantly to several drug approvals spanning neurology and psychiatry, including
drug development planning, PK/PD evaluation, and methodological innovation for Schizophrenia, Depression, Bipolar Disorder, Parkinson’s (PD), Alzheimer’s Diseases (AD), and pain indications. He has
assisted in the design, implemented, supervised, and conducted more than 100 CNS clinical trials ranging from first into patient through to proof of concept, implements Asian Bridging strategies,
and has overseen large global Phase III registration trials. He is a leader in the use of signal detection strategies to minimize placebo response. Larry has a proven track record as an
investigator, translational CNS scientist, and clinical advisor in designing and performing Phase I/IIA and clinical pharmacology studies.